Omeros Delivers Fourth Quarter Profit and Clears Major Debt with Novo Nordisk Deal: What’s Next After FDA Approval of YARTEMLEA?
Market Chameleon (Wed, 1-Apr 11:08 AM)
Novo Nordisk Deal Transforms Omeros Financials as YARTEMLEA Launch Gains Traction
Market Chameleon (Wed, 1-Apr 7:31 AM)
Omeros’ OncotoX-AML Shows Up to 99% Reduction in Leukemia-Linked Cells—Will This Change AML Treatment?
Market Chameleon (Tue, 17-Feb 9:30 AM)
